| [1] O'SULLIVAN G J,CARTY F L,CRONIN C G. Imaging of bone metastasis:An update[J]. World J Radiol,2015,7(8):202-211.[2] COLEMAN R E. Metastatic bone disease:clinical features,pathophysiology and treatment strategies[J]. Cancer Treat Rev,2001,27(3):165-176.[3] MARIZ K,INGOLF J B,DANIEL H,et al. The Wnt inhibitor Dickkopf-1:a link between breast cancer and bone metastases[J]. Clin Exp Metastasis,2015,32(8):857-866.[4] CHU T,TENG J,JIANG L,et al. Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation[J]. Biochem Biophys Res Commun,2014,443(3):962-968.[5] THUDI N K,MARTIN C K,MURAHARI S,et al. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases[J]. Prostate,2011,71(6):615-625.[6] GLINKA A,WU W,DELIUS H,et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction[J]. Nature,1998,391(6665):357-362.[7] NIEHRS C. Function and biological roles of the Dickkopf family of Wnt modulators[J]. Oncogene,2006,25(57):7469-7481.[8] VOORZANGER-ROUSSELOT N,GOEHRIG D,JOURNE F,et al. Increased Dickkopf-1 expression in breast cancer bone metastases[J]. Br J Cancer,2007,97(7):964-970.[9] HALL C L,DAIGNAULT S D,SHAH R B,et al. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis[J]. Prostate,2008,68(13):1396-1404.[10] 冯晓燕,邓书会,安刚. 血清DKK1检测在多发性骨髓瘤及其骨病中的应用[J]. 中华血液学杂志,2015,36(8):682-685.[11] IYER S P,BECK J T,STEWART A K,et al. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events[J]. Br J Haematol,2014,167(3):366-375.[12] BU G,LU W,LIU C C,et al. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression:implication for breast cancer osteolytic bone metastases[J]. Int J Cancer,2008,123(5):1034-1042.[13] HALL C L,BAFICO A,DAI J,et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts[J]. Cancer Res,2005,65(17):7554-7560.[14] MENEZES M E,DEVINE D J,SHEVDE L A,et al. Dickkopf1:a tumor suppressor or metastasis promoter?[J]. Int J Cancer,2012,130(7):1477-1483.[15] TAKAHASHI-YANAGA F,KAHN M. Targeting Wnt signaling:can we safely eradicate cancer stem cells?[J]. Clin Cancer Res,2010,16(12):3153-3162.[16] STEWART D J,CHANG D W,YE Y,et al. Wnt signaling pathway pharmacogenetics in non-small cell lung cancer[J]. Pharmacogenomics J,2014,14(6):509-522.[17] ZORN A M. Wnt signalling:antagonistic Dickkopfs[J]. Curr Biol,2001,11(15):592-595.[18] JIN H,WANG B,LI J,et al. Anti-DKK1 antibody promotes bone fracture healing through activation of beta-catenin signaling[J]. Bone,2015,71:63-75.[19] XU J,LI Z,HOU Y,et al. Potential mechanisms underlying the Runx2 induced osteogenesis of bone marrow mesenchymal stem cells[J]. Am J Transl Res,2015,7(12):2527-2535.[20] TAO K,XIAO D,WENG J,et al. Berberine promotes bone marrow-derived mesenchymal stem cells osteogenic differentiation via canonical Wnt/beta-catenin signaling pathway[J]. Toxicol Lett,2016,240(1):68-80.[21] 李书琴,杨珊,任嫒姝,等. 张应力刺激下Wnt/β-catenin信号通路对成牙骨质细胞Runx2表达调控的体外研究[J]. 华西口腔医学杂志,2015,33(1):35-39.[22] KYVERNITAKIS I,RACHNER T D,URBSCHAT A,et al. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1,bone turnover markers and bone mineral density in women with breast cancer[J]. J Cancer Res Clin Oncol,2014,140(10):1671-1680.[23] SANTINI D,GALLUZZO S,ZOCCOLI A,et al. New molecular targets in bone metastases[J]. Cancer Treat Rev,2010,36 (Sup 3):6-10.[24] LE PAPE F,VARGAS G,CLEZARDIN P. The role of osteoclasts in breast cancer bone metastasis[J]. J Bone Oncol,2016,5(3):93-95.[25] WADA T,NAKASHIMA T,HIROSHI N,et al. RANKL-RANK signaling in osteoclastogenesis and bone disease[J]. Trends Mol Med,2006,12(1):17-25.[26] PINZONE J J,HALL B M,THUDI N K,et al. The role of Dickkopf-1 in bone development,homeostasis,and disease[J]. Blood,2009,113(3):517-525.[27] TIAN E,ZHAN F,WALKER R,et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma[J]. N Engl J Med,2003,349(26):2483-2494.[28] QIANG Y W,CHEN Y,STEPHENS O,et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts:a potential mechanism underlying osteolytic bone lesions in multiple myeloma[J]. Blood,2008,112(1):196-207.[29] GARCIA-MARTIN A,REYES-GARCIA R,GARCIA-FONTANA B,et al. Relationship of Dickkopf1 (DKK1) with cardiovascular disease and bone metabolism in Caucasian type 2 diabetes mellitus[J]. PLoS One,2014,9(11):111703.[30] SMADJA D M,D'AUDIGIER C,WEISWALD L B,et al. The Wnt antagonist Dickkopf-1 increases endothelial progenitor cell angiogenic potential[J]. Arterioscler Thromb Vasc Biol,2010,30(12):2544-2552.[31] RAY S,KHASSAWNA T E,SOMMER U,et al. Differences in expression of Wnt antagonist Dkk1 in healthy versus pathological bone samples[J]. J Microsc,2016. doi:10.1111/jmi.12469.[32] NA Y,LEE S M,KIM D S,et al. Promoter methylation of Wnt antagonist DKK1 gene and prognostic value in Korean patients with non-small cell lung cancers[J]. Cancer Biomark,2012,12(2):73-79. |
